<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39439011</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2047-783X</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>22</Day></PubDate></JournalIssue><Title>European journal of medical research</Title><ISOAbbreviation>Eur J Med Res</ISOAbbreviation></Journal><ArticleTitle>Characteristics and outcomes of patients hospitalized for infection with Influenza A, SARS-CoV-2 or respiratory syncytial virus in the season 2023/2024 in a large German primary care centre.</ArticleTitle><Pagination><StartPage>509</StartPage><MedlinePgn>509</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">509</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s40001-024-02096-9</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In addition to the persistence of SARS-CoV-2 infections, those with Influenza A/B and RSV have reappeared in 2022/23. To compare the development of prevalence, clinical outcomes and risk factors, we analysed data of the season 2023/24 from the same region/hospital as for 2022/23.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients covering the whole age range with a positive polymerase chain reaction (PCR) test for SARS-CoV-2, Influenza A/B, RSV were included from the internal, neurological and paediatric units of the RoMed hospital Rosenheim, Germany/Bavaria, from August 1st 2023 to 29th February 2024.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 932 patients included, 912 showed single infections with SARS-CoV-2, Influenza A or RSV (47.9% female, median age 68.0 years; 52.9% SARS-CoV-2, 23.2% Influenza A, 21.8% RSV). Co-infections (2.0%) and Influenza B (0.1%) were negligible. In patients of age ≥ 18 years (n = 628, 68.5% SARS-CoV-2, 26.0% Influenza A, 5.6% RSV), patients with Influenza A were younger compared to SARS-CoV-2 (p &lt; 0.001), with RSV similar to SARS-CoV-2. Heart failure and asthma were the most prevalent comorbidities for RSV, immunosuppression for Influenza A. Admission to Intensive Care Unit (ICU) occurred in 111 patients (17.0% of SARS-CoV-2, 17.2% Influenza A, 28.6% RSV), and 59 patients died (8.8% SARS-CoV-2, 8.6% Influenza A, 20.0% RSV). Low-flow oxygen supplementation and non-invasive ventilation (NIV) were most frequent for RSV (68.6% and 20.0%, respectively), oxygen demand upon admission for Influenza A (39.3%), without differences in high-flow oxygen supply or length of hospital stay. Among patients aged &lt; 18 years (n = 284, 21.4% SARS-CoV-2, 18.0% Influenza A, 57.1% RSV), 15 were admitted to ICU (4.8% SARS-CoV-2, 3.8% Influenza A, 6.0% RSV); none of them died. Oxygen supply via high-flow, low-flow or upon admission was highest for RSV (23.8%, 70.2%, 21.4%, respectively), as well as the length of hospital stay.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Between 8/2023 to 2/2024, a large population of patients hospitalized due to respiratory tract infection, showed relative contributions of SARS-CoV-2, Influenza A or RSV similar to those in 2022/23. The findings underline that in both, adults and children, RSV posed a relatively higher clinical risk than Influenza A and SARS-CoV-2, though absolute numbers remained highest for SARS-CoV-2.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wiechert</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine III, Division of Pneumology and Respiratory Medicine, RoMed Hospital Rosenheim, Ellmaierstraße 23, 83022, Rosenheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fischer</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medicine I, Division of Respiratory Diseases, School of Medicine &amp; Klinikum Rechts Der Isar, Technical University of Munich, Ismaninger Straße 22, 81675, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, LMU Hospital, Member of the German Center for Lung Research (DZL), Comprehensive Pneumology Center Munich (CPC-M), Ziemssenstraße 1, 80336, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jörres</LastName><ForeName>R A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, LMU Hospital, Member of the German Center for Lung Research (DZL), Comprehensive Pneumology Center Munich (CPC-M), Ziemssenstraße 1, 80336, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Engelhardt</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine III, Division of Pneumology and Respiratory Medicine, RoMed Hospital Rosenheim, Ellmaierstraße 23, 83022, Rosenheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alter</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medicine, Pulmonary and Critical Care Medicine, Member of the German Center for Lung Research (DZL), University of Marburg (UMR), Baldingerstraße, 35043, Marburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kahnert</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>MediCenterGermering, Hartstraße 53, 82110, Germering, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine V, LMU University Hospital, LMU Munich, German Center for Lung Research (DZL), Comprehensive Pneumology Center Munich (CPC-M), Marchioninstraße 15, 81377, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Budweiser</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine III, Division of Pneumology and Respiratory Medicine, RoMed Hospital Rosenheim, Ellmaierstraße 23, 83022, Rosenheim, Germany. Stephan.budweiser@ro-med.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine II, University Hospital Regensburg, 93053, Regensburg, Germany. Stephan.budweiser@ro-med.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Med Res</MedlineTA><NlmUniqueID>9517857</NlmUniqueID><ISSNLinking>0949-2321</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="Y">Influenza, Human</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018357" MajorTopicYN="Y">Respiratory Syncytial Virus Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="Y">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009980" MajorTopicYN="N">Influenza A virus</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012621" MajorTopicYN="N">Seasons</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>23</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>23</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>23</Day><Hour>0</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39439011</ArticleId><ArticleId IdType="pmc">PMC11495040</ArticleId><ArticleId IdType="doi">10.1186/s40001-024-02096-9</ArticleId><ArticleId IdType="pii">10.1186/s40001-024-02096-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brigadoi G, Demarin GC, Boracchini R, Pierantoni L, Rossin S, Barbieri E, et al. Comparison between the viral illness caused by SARS-CoV-2, Influenza virus, respiratory syncytial virus and other respiratory viruses in pediatrics. Viruses. 2024;16(2):199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10891516</ArticleId><ArticleId IdType="pubmed">38399975</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciofi Degli Atti ML, Beccia F, D’Amore C, Ravà L, Bernaschi P, Russo C, et al. Impact of SARS-CoV-2 pandemic on emergency hospitalizations for acute respiratory infections: the experience of a paediatric tertiary care hospital in Italy. Influenza Other Respir Viruses. 2024;18(6):13335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11184210</ArticleId><ArticleId IdType="pubmed">38887843</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandeel A, Fahim M, Deghedy O, Roshdy WH, Khalifa MK, Shesheny RE, et al. Resurgence of influenza and respiratory syncytial virus in Egypt following two years of decline during the COVID-19 pandemic: outpatient clinic survey of infants and children, October 2022. BMC Public Health. 2023;23(1):1067.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10240446</ArticleId><ArticleId IdType="pubmed">37277781</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez A, Lively JY, Curns A, Weinberg GA, Halasa NB, Staat MA, New Vaccine Surveillance Network Collaborators, et al. Respiratory virus surveillance among children with acute respiratory illnesses—new vaccine surveillance network, United States, 2016–2021. MMWR Morb Mortal Wkly Rep. 2022;71(40):1253–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9541034</ArticleId><ArticleId IdType="pubmed">36201373</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi T, McLean K, Campbell H, Nair H. Aetiological role of common respiratory viruses in acute lower respiratory infections in children under five years: a systematic review and meta-analysis. J Glob Health. 2015;5(1): 010408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4593292</ArticleId><ArticleId IdType="pubmed">26445672</ArticleId></ArticleIdList></Reference><Reference><Citation>Terliesner N, Unterwalder N, Edelmann A, Corman V, Knaust A, Rosenfeld L, et al. Viral infections in hospitalized children in Germany during the COVID-19 pandemic: association with non-pharmaceutical interventions. Front Pediatr. 2022;11(10): 935483.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9403271</ArticleId><ArticleId IdType="pubmed">36034546</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackerson B, Tseng HF, Sy LS, Solano Z, Slezak J, Luo Y, et al. Severe morbidity and mortality associated with respiratory syncytial virus versus Influenza infection in hospitalized older adults. Clin Infect Dis. 2019;69(2):197–203.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6603263</ArticleId><ArticleId IdType="pubmed">30452608</ArticleId></ArticleIdList></Reference><Reference><Citation>Surie D, Yuengling KA, DeCuir J, Zhu Y, Lauring AS, Gaglani M, et al. Severity of Respiratory syncytial virus vs COVID-19 and influenza among hospitalized US adults. JAMA Netw Open. 2024;7(40): e244954.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11192181</ArticleId><ArticleId IdType="pubmed">38573635</ArticleId></ArticleIdList></Reference><Reference><Citation>Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005;352(17):1749–59.</Citation><ArticleIdList><ArticleId IdType="pubmed">15858184</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X, Wang Q, Wang M, Su X, Xing Z, Zhang W, et al. Incidence of respiratory viral infections detected by PCR and real-time PCR in adult patients with community-acquired pneumonia: a meta-analysis. Respiration. 2015;89(4):343–52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7179531</ArticleId><ArticleId IdType="pubmed">25791384</ArticleId></ArticleIdList></Reference><Reference><Citation>Stamm P, Sagoschen I, Weise K, Plachter B, Münzel T, Gori T, et al. Influenza and RSV incidence during COVID-19 pandemic-an observational study from in-hospital point-of-care testing. Med Microbiol Immunol. 2021;210(5–6):277–82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8487758</ArticleId><ArticleId IdType="pubmed">34604931</ArticleId></ArticleIdList></Reference><Reference><Citation>Groves HE, Piché-Renaud PP, Peci A, Farrar DS, Buckrell S, Bancej C, et al. The impact of the COVID-19 pandemic on influenza, respiratory syncytial virus, and other seasonal respiratory virus circulation in Canada: a population-based study. Lancet Reg Health Am. 2021;1: 100015.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8285668</ArticleId><ArticleId IdType="pubmed">34386788</ArticleId></ArticleIdList></Reference><Reference><Citation>Buda S, Dürrwald R, Biere B, Buchholz U, Tolksdorf K, Schilling J et al. ARE-Wochenbericht KW 52–53/2020.</Citation></Reference><Reference><Citation>Diniz LM, Dias CS, Oliveira MCL, Simões E Silva AC, Colosimo EA, Mak RH, et al. Outcomes of SARS-CoV-2 and seasonal viruses among 2 million adults hospitalized for severe acute respiratory infection during the COVID-19 pandemic in Brazil. J Infect Dis. 2024. 10.1093/infdis/jiae295.</Citation><ArticleIdList><ArticleId IdType="pubmed">38820088</ArticleId></ArticleIdList></Reference><Reference><Citation>Quarg C, Jörres RA, Engelhardt S, Alter P, Budweiser S. Characteristics and outcomes of patients hospitalized for infection with influenza, SARS-CoV-2 or respiratory syncytial virus in the season 2022/2023 in a large German primary care centre. Eur J Med Res. 2023;28(1):568.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10699044</ArticleId><ArticleId IdType="pubmed">38053110</ArticleId></ArticleIdList></Reference><Reference><Citation>Heiland LM, Jörres R, Engelhardt S, Alter P, Kahnert K, Deerberg-Wittram J, et al. Retrospective clinical-causal evaluation of a positive PCR for SARS-CoV-2 in hospitalised patients across the age spectrum in a primary care hospital. Pneumologie. 2024;78(2):100–6 (German).</Citation><ArticleIdList><ArticleId IdType="pubmed">37857321</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton MA, Liu Y, Calzavara A, Sundaram ME, Djebli M, Darvin D, et al. Predictors of all-cause mortality among patients hospitalized with influenza, respiratory syncytial virus, or SARS-CoV-2. Influenza Other Respir Viruses. 2022;16(6):1072–81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9347457</ArticleId><ArticleId IdType="pubmed">35611399</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambrosch A, Luber D, Klawonn F, Kabesch M. Focusing on severe infections with the respiratory syncytial virus (RSV) in adults: risk factors, symptomatology and clinical course compared to influenza A/B and the original SARS-CoV-2 strain. J Clin Virol. 2023;161: 105399.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9927795</ArticleId><ArticleId IdType="pubmed">36863135</ArticleId></ArticleIdList></Reference><Reference><Citation>Buda S, Dürrwald R, Biere B, Reiche J, Buchholz U, Tolksdorf K et al. ARE-Wochenbericht KW 29/2024.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>